Annual EBIT
-$250.92 M
+$85.15 M+25.34%
31 December 2023
Summary:
Nektar Therapeutics annual earnings before interest & taxes is currently -$250.92 million, with the most recent change of +$85.15 million (+25.34%) on 31 December 2023. During the last 3 years, it has risen by +$155.91 million (+38.32%). NKTR annual EBIT is now -134.59% below its all-time high of $736.37 million.NKTR EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$31.03 M
+$14.88 M+32.41%
30 September 2024
Summary:
Nektar Therapeutics quarterly earnings before interest & taxes is currently -$31.03 million, with the most recent change of +$14.88 million (+32.41%) on 30 September 2024. Over the past year, it has increased by +$8.96 million (+22.41%). NKTR quarterly EBIT is now -103.15% below its all-time high of $985.71 million, reached on 30 June 2018.NKTR Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$143.48 M
+$8.96 M+5.88%
30 September 2024
Summary:
Nektar Therapeutics TTM earnings before interest & taxes is currently -$143.48 million, with the most recent change of +$8.96 million (+5.88%) on 30 September 2024. Over the past year, it has increased by +$121.54 million (+45.86%). NKTR TTM EBIT is now -115.12% below its all-time high of $948.94 million, reached on 30 June 2018.NKTR TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NKTR EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +25.3% | +22.4% | +45.9% |
| 3 y3 years | +38.3% | +73.4% | +67.9% |
| 5 y5 years | -134.6% | +64.4% | +62.5% |
NKTR EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +47.3% | at high | +79.5% | at high | +70.7% |
| 5 y | 5 years | -134.6% | +47.3% | at high | +79.5% | at high | +70.7% |
| alltime | all time | -134.6% | +47.3% | -103.2% | +79.5% | -115.1% | +70.7% |
Nektar Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$31.03 M(-32.4%) | -$143.48 M(-5.9%) |
| June 2024 | - | -$45.91 M(+46.6%) | -$152.44 M(+0.6%) |
| Mar 2024 | - | -$31.31 M(-11.2%) | -$151.55 M(-39.6%) |
| Dec 2023 | -$250.92 M(-25.3%) | -$35.24 M(-11.9%) | -$250.92 M(-5.3%) |
| Sept 2023 | - | -$39.99 M(-11.2%) | -$265.02 M(-4.4%) |
| June 2023 | - | -$45.02 M(-65.6%) | -$277.29 M(-27.8%) |
| Mar 2023 | - | -$130.68 M(+164.8%) | -$384.01 M(+14.3%) |
| Dec 2022 | -$336.07 M(-29.4%) | -$49.34 M(-5.6%) | -$336.07 M(-20.8%) |
| Sept 2022 | - | -$52.25 M(-65.6%) | -$424.25 M(-13.2%) |
| June 2022 | - | -$151.74 M(+83.4%) | -$488.79 M(+8.8%) |
| Mar 2022 | - | -$82.74 M(-39.8%) | -$449.13 M(-5.6%) |
| Dec 2021 | -$475.97 M(+17.0%) | -$137.52 M(+17.7%) | -$475.97 M(+6.4%) |
| Sept 2021 | - | -$116.79 M(+4.2%) | -$447.34 M(+3.9%) |
| June 2021 | - | -$112.07 M(+2.3%) | -$430.68 M(+10.1%) |
| Mar 2021 | - | -$109.58 M(+0.6%) | -$391.13 M(-3.9%) |
| Dec 2020 | -$406.83 M(+3.3%) | -$108.89 M(+8.7%) | -$406.83 M(+2.4%) |
| Sept 2020 | - | -$100.14 M(+38.1%) | -$397.20 M(+3.4%) |
| June 2020 | - | -$72.52 M(-42.1%) | -$384.31 M(-6.4%) |
| Mar 2020 | - | -$125.28 M(+26.2%) | -$410.77 M(+4.3%) |
| Dec 2019 | -$393.70 M(-154.3%) | -$99.27 M(+13.8%) | -$393.70 M(+2.9%) |
| Sept 2019 | - | -$87.25 M(-11.9%) | -$382.68 M(+0.1%) |
| June 2019 | - | -$98.98 M(-8.5%) | -$382.22 M(-154.4%) |
| Mar 2019 | - | -$108.20 M(+22.6%) | $702.47 M(-3.2%) |
| Dec 2018 | $725.50 M(-1416.2%) | -$88.25 M(+1.7%) | $725.50 M(-8.3%) |
| Sept 2018 | - | -$86.79 M(-108.8%) | $791.07 M(-16.6%) |
| June 2018 | - | $985.71 M(-1257.4%) | $948.94 M(-1196.9%) |
| Mar 2018 | - | -$85.17 M(+275.6%) | -$86.51 M(+56.9%) |
| Dec 2017 | -$55.12 M(-50.1%) | -$22.68 M(-131.9%) | -$55.12 M(-13.7%) |
| Sept 2017 | - | $71.08 M(-242.9%) | -$63.87 M(-61.9%) |
| June 2017 | - | -$49.75 M(-7.5%) | -$167.52 M(+7.6%) |
| Mar 2017 | - | -$53.78 M(+71.1%) | -$155.64 M(+40.9%) |
| Dec 2016 | -$110.47 M(+164.5%) | -$31.42 M(-3.5%) | -$110.47 M(-9.6%) |
| Sept 2016 | - | -$32.57 M(-14.0%) | -$122.16 M(+38.4%) |
| June 2016 | - | -$37.87 M(+339.9%) | -$88.28 M(-5.7%) |
| Mar 2016 | - | -$8.61 M(-80.0%) | -$93.63 M(+124.2%) |
| Dec 2015 | -$41.77 M(+166.5%) | -$43.12 M(-3374.0%) | -$41.77 M(+16.5%) |
| Sept 2015 | - | $1.32 M(-103.0%) | -$35.86 M(-182.9%) |
| June 2015 | - | -$43.22 M(-199.9%) | $43.27 M(-32.0%) |
| Mar 2015 | - | $43.25 M(-216.2%) | $63.67 M(-506.3%) |
| Dec 2014 | -$15.67 M(-86.8%) | -$37.21 M(-146.3%) | -$15.67 M(+9.9%) |
| Sept 2014 | - | $80.45 M(-452.5%) | -$14.26 M(-85.9%) |
| June 2014 | - | -$22.82 M(-36.8%) | -$100.85 M(-8.7%) |
| Mar 2014 | - | -$36.09 M(+0.8%) | -$110.43 M(-7.2%) |
| Dec 2013 | -$119.01 M(-13.7%) | -$35.79 M(+482.3%) | -$119.01 M(-5.6%) |
| Sept 2013 | - | -$6.15 M(-81.0%) | -$126.07 M(-17.1%) |
| June 2013 | - | -$32.40 M(-27.5%) | -$152.07 M(+4.2%) |
| Mar 2013 | - | -$44.66 M(+4.2%) | -$145.93 M(+5.8%) |
| Dec 2012 | -$137.90 M(+12.4%) | -$42.86 M(+33.4%) | -$137.90 M(+6.7%) |
| Sept 2012 | - | -$32.14 M(+22.4%) | -$129.29 M(+9.0%) |
| June 2012 | - | -$26.26 M(-28.3%) | -$118.59 M(-5.9%) |
| Mar 2012 | - | -$36.64 M(+7.0%) | -$126.08 M(+2.7%) |
| Dec 2011 | -$122.74 M(+374.2%) | -$34.25 M(+59.8%) | -$122.74 M(+13.3%) |
| Sept 2011 | - | -$21.43 M(-36.5%) | -$108.31 M(+17.1%) |
| June 2011 | - | -$33.75 M(+1.4%) | -$92.49 M(+64.2%) |
| Mar 2011 | - | -$33.30 M(+67.9%) | -$56.31 M(+117.6%) |
| Dec 2010 | -$25.88 M(-71.4%) | -$19.83 M(+253.6%) | -$25.88 M(+145.5%) |
| Sept 2010 | - | -$5.61 M(-331.4%) | -$10.54 M(-68.2%) |
| June 2010 | - | $2.42 M(-184.4%) | -$33.11 M(-48.9%) |
| Mar 2010 | - | -$2.87 M(-36.0%) | -$64.86 M(-28.4%) |
| Dec 2009 | -$90.60 M | -$4.49 M(-84.1%) | -$90.60 M(-2516.5%) |
| Sept 2009 | - | -$28.18 M(-3.9%) | $3.75 M(-242.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$29.33 M(+2.5%) | -$2.63 M(-60.5%) |
| Mar 2009 | - | -$28.60 M(-131.8%) | -$6.66 M(-66.6%) |
| Dec 2008 | -$19.95 M(-44.8%) | $89.86 M(-360.0%) | -$19.95 M(-72.5%) |
| Sept 2008 | - | -$34.56 M(+3.6%) | -$72.43 M(+26.1%) |
| June 2008 | - | -$33.36 M(-20.4%) | -$57.44 M(+10.3%) |
| Mar 2008 | - | -$41.89 M(-212.1%) | -$52.07 M(+44.0%) |
| Dec 2007 | -$36.15 M(-77.3%) | $37.38 M(-291.0%) | -$36.15 M(-68.2%) |
| Sept 2007 | - | -$19.57 M(-30.1%) | -$113.69 M(-2.7%) |
| June 2007 | - | -$27.99 M(+7.8%) | -$116.80 M(-23.2%) |
| Mar 2007 | - | -$25.97 M(-35.3%) | -$152.03 M(-4.5%) |
| Dec 2006 | -$159.23 M(-8.9%) | -$40.16 M(+77.1%) | -$159.23 M(-27.6%) |
| Sept 2006 | - | -$22.68 M(-64.1%) | -$219.93 M(-0.3%) |
| June 2006 | - | -$63.21 M(+90.5%) | -$220.62 M(+20.0%) |
| Mar 2006 | - | -$33.17 M(-67.1%) | -$183.86 M(+5.2%) |
| Dec 2005 | -$174.77 M(+136.4%) | -$100.86 M(+331.7%) | -$174.77 M(+89.3%) |
| Sept 2005 | - | -$23.37 M(-11.7%) | -$92.31 M(+5.2%) |
| June 2005 | - | -$26.45 M(+9.8%) | -$87.77 M(+6.5%) |
| Mar 2005 | - | -$24.09 M(+30.9%) | -$82.44 M(+11.2%) |
| Dec 2004 | -$73.94 M(+11.7%) | -$18.40 M(-2.3%) | -$74.15 M(-2.0%) |
| Sept 2004 | - | -$18.83 M(-10.8%) | -$75.66 M(+6.6%) |
| June 2004 | - | -$21.12 M(+33.6%) | -$70.97 M(+10.1%) |
| Mar 2004 | - | -$15.81 M(-20.6%) | -$64.45 M(-2.6%) |
| Dec 2003 | -$66.19 M(-33.9%) | -$19.91 M(+40.9%) | -$66.19 M(-12.4%) |
| Sept 2003 | - | -$14.13 M(-3.2%) | -$75.52 M(-12.2%) |
| June 2003 | - | -$14.60 M(-16.7%) | -$85.97 M(-8.6%) |
| Mar 2003 | - | -$17.54 M(-40.0%) | -$94.04 M(-6.0%) |
| Dec 2002 | -$100.08 M(-9.6%) | -$29.24 M(+19.0%) | -$100.08 M(-3.4%) |
| Sept 2002 | - | -$24.58 M(+8.4%) | -$103.64 M(-3.6%) |
| June 2002 | - | -$22.68 M(-3.8%) | -$107.55 M(-3.1%) |
| Mar 2002 | - | -$23.58 M(-28.1%) | -$111.01 M(+0.3%) |
| Dec 2001 | -$110.70 M(+73.4%) | -$32.80 M(+15.1%) | -$110.70 M(+15.6%) |
| Sept 2001 | - | -$28.49 M(+9.0%) | -$95.73 M(+15.1%) |
| June 2001 | - | -$26.14 M(+12.3%) | -$83.18 M(+15.0%) |
| Mar 2001 | - | -$23.27 M(+30.5%) | -$72.35 M(+13.3%) |
| Dec 2000 | -$63.85 M(+108.7%) | -$17.84 M(+11.9%) | -$63.85 M(+13.8%) |
| Sept 2000 | - | -$15.94 M(+4.2%) | -$56.09 M(+17.3%) |
| June 2000 | - | -$15.30 M(+3.6%) | -$47.82 M(+22.2%) |
| Mar 2000 | - | -$14.77 M(+46.6%) | -$39.12 M(+28.1%) |
| Dec 1999 | -$30.59 M(+39.1%) | -$10.08 M(+31.4%) | -$30.55 M(+12.1%) |
| Sept 1999 | - | -$7.67 M(+16.2%) | -$27.26 M(+7.4%) |
| June 1999 | - | -$6.60 M(+6.5%) | -$25.39 M(+11.5%) |
| Mar 1999 | - | -$6.20 M(-8.7%) | -$22.78 M(+4.2%) |
| Dec 1998 | -$21.99 M(+60.2%) | -$6.79 M(+17.1%) | -$21.86 M(+12.9%) |
| Sept 1998 | - | -$5.80 M(+45.3%) | -$19.37 M(+13.7%) |
| June 1998 | - | -$3.99 M(-24.4%) | -$17.03 M(+4.9%) |
| Mar 1998 | - | -$5.28 M(+22.7%) | -$16.23 M(+18.5%) |
| Dec 1997 | -$13.72 M(+19.3%) | -$4.30 M(+24.1%) | -$13.69 M(+3.8%) |
| Sept 1997 | - | -$3.46 M(+8.6%) | -$13.20 M(+6.1%) |
| June 1997 | - | -$3.19 M(+16.2%) | -$12.43 M(+1.5%) |
| Mar 1997 | - | -$2.74 M(-27.8%) | -$12.24 M(+5.6%) |
| Dec 1996 | -$11.50 M(+30.7%) | -$3.80 M(+40.7%) | -$11.60 M(+12.6%) |
| Sept 1996 | - | -$2.70 M(-10.0%) | -$10.30 M(+7.3%) |
| June 1996 | - | -$3.00 M(+42.9%) | -$9.60 M(+11.6%) |
| Mar 1996 | - | -$2.10 M(-16.0%) | -$8.60 M(-2.3%) |
| Dec 1995 | -$8.80 M(+54.4%) | -$2.50 M(+25.0%) | -$8.80 M(+1.1%) |
| Sept 1995 | - | -$2.00 M(0.0%) | -$8.70 M(+11.5%) |
| June 1995 | - | -$2.00 M(-13.0%) | -$7.80 M(+13.0%) |
| Mar 1995 | - | -$2.30 M(-4.2%) | -$6.90 M(+23.2%) |
| Dec 1994 | -$5.70 M | -$2.40 M(+118.2%) | -$5.60 M(+75.0%) |
| Sept 1994 | - | -$1.10 M(0.0%) | -$3.20 M(+52.4%) |
| June 1994 | - | -$1.10 M(+10.0%) | -$2.10 M(+110.0%) |
| Mar 1994 | - | -$1.00 M | -$1.00 M |
FAQ
- What is Nektar Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Nektar Therapeutics?
- What is Nektar Therapeutics annual EBIT year-on-year change?
- What is Nektar Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Nektar Therapeutics?
- What is Nektar Therapeutics quarterly EBIT year-on-year change?
- What is Nektar Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Nektar Therapeutics?
- What is Nektar Therapeutics TTM EBIT year-on-year change?
What is Nektar Therapeutics annual earnings before interest & taxes?
The current annual EBIT of NKTR is -$250.92 M
What is the all time high annual EBIT for Nektar Therapeutics?
Nektar Therapeutics all-time high annual earnings before interest & taxes is $736.37 M
What is Nektar Therapeutics annual EBIT year-on-year change?
Over the past year, NKTR annual earnings before interest & taxes has changed by +$85.15 M (+25.34%)
What is Nektar Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of NKTR is -$31.03 M
What is the all time high quarterly EBIT for Nektar Therapeutics?
Nektar Therapeutics all-time high quarterly earnings before interest & taxes is $985.71 M
What is Nektar Therapeutics quarterly EBIT year-on-year change?
Over the past year, NKTR quarterly earnings before interest & taxes has changed by +$8.96 M (+22.41%)
What is Nektar Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of NKTR is -$143.48 M
What is the all time high TTM EBIT for Nektar Therapeutics?
Nektar Therapeutics all-time high TTM earnings before interest & taxes is $948.94 M
What is Nektar Therapeutics TTM EBIT year-on-year change?
Over the past year, NKTR TTM earnings before interest & taxes has changed by +$121.54 M (+45.86%)